- Record: found
- Abstract: found
- Article: not found
The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation.
Martijn P Lolkema
1
,
2 ,
Hilde H Bohets
3 ,
Hendrik-Tobias Arkenau
1 ,
Ann Lampo
3 ,
Erio Barale
3 ,
Maja J A de Jonge
2 ,
Leni van Doorn
2 ,
Peter Hellemans
3 ,
Johann S de Bono
1 ,
Ferry A L M Eskens
2
May 15 2015
Read this article at
ScienceOpenPublisherPMC
- open (via free pdf)
- oa repository (via OAI-PMH doi match)
- oa repository (via OAI-PMH doi match)
- oa repository (via OAI-PMH doi match)
- oa repository (via pmcid lookup)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
Powered by 
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The receptor tyrosine kinase c-Met plays an important role in tumorigenesis and is a novel target for anticancer treatment. This phase I, first-in-human trial, explored safety, pharmacokinetics, pharmacodynamics, and initial antitumor activity of JNJ-38877605, a potent and selective c-Met inhibitor.